Madrigal Pharmaceuticals, Inc. (FRA:YDO1)
Germany · Delayed Price · Currency is EUR | Market Cap | 11.32B |
| Revenue (ttm) | 631.25M |
| Net Income (ttm) | -246.42M |
| Shares Out | n/a |
| EPS (ttm) | -11.11 |
| PE Ratio | n/a |
| Forward PE | 126.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10 |
| Average Volume | 5 |
| Open | 516.00 |
| Previous Close | 513.20 |
| Day's Range | 508.60 - 516.00 |
| 52-Week Range | 229.50 - 523.20 |
| Beta | n/a |
| RSI | 73.61 |
| Earnings Date | Feb 25, 2026 |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. [Read more]
News
Madrigal Pharmaceuticals (MDGL) Sees Analyst Upgrade with Target Price Raised to $620 | MDGL ...
Madrigal Pharmaceuticals (MDGL) Sees Analyst Upgrade with Target Price Raised to $620 | MDGL Stock News
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript
Madrigal Pharmaceuticals (MDGL): Oppenheimer Raises Price Target to $650 | MDGL Stock News
Madrigal Pharmaceuticals (MDGL): Oppenheimer Raises Price Target to $650 | MDGL Stock News
Madrigal Pharmaceuticals (MDGL) Rating Maintained and Price Target Raised by Truist Securities ...
Madrigal Pharmaceuticals (MDGL) Rating Maintained and Price Target Raised by Truist Securities | MDGL Stock News
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor confer...
Madrigal Pharmaceuticals (MDGL): Analyst Maintains Buy Rating, Raises Price Target | MDGL Stock News
Madrigal Pharmaceuticals (MDGL): Analyst Maintains Buy Rating, Raises Price Target | MDGL Stock News
MDGL Crosses Above Average Analyst Target
In recent trading, shares of Madrigal Pharmaceuticals Inc (Symbol: MDGL) have crossed above the average analyst 12-month target price of $521.50, changing hands for $541.50/share. When a stock reaches...
Madrigal Pharmaceuticals (MDGL) Receives Buy Rating and Price Target Increase | MDGL Stock News
Madrigal Pharmaceuticals (MDGL) Receives Buy Rating and Price Target Increase | MDGL Stock News
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
Rezdiffra ® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra ...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ...
Madrigal Pharmaceuticals (MDGL) Sees Stock Surge After Q3 Revenue Beat
Madrigal Pharmaceuticals (MDGL) Sees Stock Surge After Q3 Revenue Beat
Madrigal upgraded at Cantor on Rezdiffra launch
Madrigal Pharmaceuticals (MDGL) stock continues to rise as Cantor Fitzgerald upgrades, citing a strong commercial launch for its liver drug Rezdiffra. Read more here.
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT Insight
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT Insight
Madrigal Pharmaceuticals Inc (MDGL) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ...
Madrigal Pharmaceuticals Inc (MDGL) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Global Expansion
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript
Noteworthy Tuesday Option Activity: MDGL, HOG, SRPT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Madrigal Pharmaceuticals Inc (Symbol: MDGL), where a total of 2,149 contracts have traded s...
Q3 2025 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Q3 2025 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Madrigal Pharmaceuticals (MDGL) Reports Strong Q3 Revenue Boost
Madrigal Pharmaceuticals (MDGL) Reports Strong Q3 Revenue Boost
Madrigal Pharmaceuticals Q3 2025 Earnings: EPS Misses, Revenue Surpasses Estimates with $287. ...
Madrigal Pharmaceuticals Q3 2025 Earnings: EPS Misses, Revenue Surpasses Estimates with $287.3 Million
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
Third -quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025 , more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral...
A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast
Madrigal Pharmaceuticals (NASDAQ: MDGL) is set to give its latest quarterly earnings report on Tuesday, 2025-11-04. Here's what investors need to know before the announcement. Analysts estimate that ...
Madrigal Pharmaceuticals Q3 2025 Earnings Preview
Madrigal Pharmaceuticals (MDGL) Upgraded to Neutral by BofA on Rezdiffra Sales
Madrigal Pharmaceuticals (MDGL) Upgraded to Neutral by BofA on Rezdiffra Sales